HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.

Disease Spotlight: NMOSD

The NeurologyLive® NMOSD Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with neuromyelitis optica spectrum disorder.

Blocking B Cells may be the Key to Controlling NMOSD Over Time

September 15th 2022

Rituximab Displays Superiority to Azathioprine, Mycophenolate Mofetil as Initial NMOSD Treatment

September 13th 2022

Among a cohort of more than 300 patients in China, those with APQ4 positive NMOSD reported a significantly lower risk of relapse among those treated with rituximab compared with the other groups.

The Patient Perspective on Neuromyelitis Optica Spectrum Disorder: Sumaira Ahmed

September 8th 2022

The founder and executive director of the Sumaira Foundation offered her perspective on the patient journey in NMOSD and the vital need to increase awareness [WATCH TIME: 9 minutes]

Abnormal Activation of BTK/NF-kB Identified in Acute, Remitted Cases of NMOSD

August 22nd 2022

CXCL2 and CXCL12, known to induce B-cell proliferation and differentiation, were significantly higher in those with acute and remitted cases of NMOSD compared with controls.

Germinal Center Activity Shows Potential As Target of Rituximab in NMOSD

August 17th 2022

Data assessing samples of deep cervical lymph node aspirates and blood suggest that germinal center activity was associated with clinical relapses in individuals with neuromyelitis optica spectrum disorder.

Long-term Immunosuppression Treatment Is Suitable for Patients With NMOSD

August 16th 2022

Data suggest that long-term treatment with immunosuppression therapies, such as rituximab, is generally appropriate for patients with neuromyelitis optica, though transverse myelitis might indicate a higher risk of relapse post discontinuation.

Characteristics of Bilateral Parafalcine Cortical Leptomeningeal Impairment in NMOSD, MOGAD Identified to Avoid Misdiagnosis

August 8th 2022

BPCLI was observed in both NMOSD and MOGAD but was relatively rarer in AQP4 NMOSD, with meningoencephalitis-like episodes among the sources of misdiagnosis.

NeurologyLive® Brain Games: August 7, 2022

August 7th 2022

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromyelitis optica spectrum disorder.

Greater Link Identified in NMOSD Between Time-Varying Functional Connectivity and Depressive Symptoms Than Static Connectivity

August 5th 2022

In a cohort of patients with NMOSD, more severe depressive symptoms were associated with increased time-varying functional connectivity between the precuneus and temporal cortex.

Cerebrospinal GFAP Levels in Double-Seronegative NMOSD Indicate Different Pathology

July 19th 2022

Using rigorous cell-based assays, cerebrospinal fluid GFAP levels were significantly lower in double-seronegative NMOSD than AQP4-positive NMOSD but did not differ between those with MOGAD or other neurological diseases.